Novo Nordisk Faces Sell-Off on Weak Outlook
Watch: Q1 2026 earnings in late April will reveal whether sales guidance is revised down further, confirming the pace of Lilly's market share gains.
Full analysis
Novo Nordisk shares plunged 41.11% in the past year, closing at $37.98 on April 13. Vltava Fund sold its position in Q1 2026, citing a deteriorating financial outlook and unpredictable future. Despite 55 hedge funds holding shares at end-2025, institutional sentiment appears cautious amid ongoing margin compression and share loss to Lilly.
The sell-off reflects fundamental concerns over Novo Nordisk's profitability and market share erosion, potentially prolonging the stock's downtrend and undermining recovery prospects.
Evidence
Get alerted when NVO changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.